ClinicalTrials.gg
CompletedNCT01429701Updated Feb 24, 2021

Effectiveness of Polymyxin B Sulphate + Prednisolone + Benzocaine + Clioquinol in Acute and Sub-acute Dermatitis Eczematous

A Phase 3 interventional study of polymyxin B sulphate + prednisolone + benzocaine + clioquinol and betamethasone + gentamicin + tolnaftato + cleoquinol in Eczema, sponsored by EMS. Completed. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2021-02-24.

Sponsored by EMS · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

Dermatitis eczematous is a recurrent pruritic skin disorder which has a significant morbidity and impaired quality of life due specially pruritus and physical visible skin lesions. The purpose of this trial is evaluate the effectiveness of two different topic associations of drugs.

Read the detailed description

Study design:

  • Experiment duration: 22 days
  • 2 visits (days 0,7,15 and 22)
  • Reducing eczema area and severity index evaluation
  • Adverse events evaluation
  • Double blinded, non-inferiority, prospective parallel-group, intend to treat trial.
02

Conditions studied

  • Eczema

Keywords

  • Dermatitis
  • Dermatitis, Atopic
03

In context

Eczema

506 studies on the registry are indexed under Eczema; 90 are open to participants now.

This study's enrollment of 76 is below the median of 91 across 403 interventional studies indexed under Eczema.

Browse Eczema studies →

Lead sponsor

EMS is the lead sponsor of 84 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must be able to understand the study procedures agree to participate and give written consent.
  2. Patients with acute or subacute dermatitis with a minimum of 3 symptoms.

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy or risk of pregnancy.
  2. Lactation
  3. Use of anti-inflammatory or drugs (last 30 days prior to the study).
  4. Sunlight over exposure in the last 15 days.
  5. Any pathology or past medical condition that can interfere with this protocol.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Test association cream

    polymyxin B sulphate + prednisolone + benzocaine + clioquinol

    Drug: polymyxin B sulphate + prednisolone + benzocaine + clioquinol

  • Active comparator
    Comparative association cream

    betamethasone + gentamicin + tolnaftato + clioquinol

    Drug: betamethasone + gentamicin + tolnaftato + cleoquinol

Interventions

  • Drugpolymyxin B sulphate + prednisolone + benzocaine + clioquinol

    Drug pages: Polymyxin B · Prednisolone · Benzocaine · Clioquinol

    applied 3 times / day at lesion

  • Drugbetamethasone + gentamicin + tolnaftato + cleoquinol

    applied 3 times / day at lesion

06

What researchers measure

Primary outcomes

  1. Reduction / improvement of signs and symptoms

    The reduction of signs and symptoms will be evaluated by OSAAD index.

    Time frame: DAY 22

Secondary outcomes

  1. Adverse Events Evaluation

    Adverse events will be collected and followed in order to evaluate safety and tolerability.

    Time frame: DAY 22

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Jun 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2011
First posted
Sep 7, 2011
Start
May 2012
Primary completionActual
Jun 2012
CompletionActual
Aug 2012
Last update
Feb 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01429701
Lead sponsor
EMS
Responsible party
Sponsor
First posted
Sep 7, 2011
Start date
May 2012
Primary completion
Jun 2012
Completion
Aug 2012
Last update
Feb 24, 2021

Study contacts

Flávia Addór, MD.
principal investigator · Medicin Instituto da Pele

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Polymyxin B · Prednisolone · Benzocaine · Clioquinol

Start the discussion